With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets. In this scenario nuclear medicine offers many radiopharmaceuticals for SPECT or PET imaging of many pathological conditions. The availability of monoclonal antibodies provides tools to target specific antigens involved in angiogenesis, cell cycle or modulation of the immune systems. The radiolabelling of such therapeutic mAbs is a promising method to evaluate the antigenic status of each cancer lesion or inflamed sites before starting the therapy. It may also allow to perform follow-up of such biological therapies. In the present review we provide an overview of the most studied radiolabelled antibodies for therapy decision making and follow-up of patients affected by cancer and other pathological conditions.

Immunoscintigraphy for therapy decision making and follow-up of biological therapies / Lauri, Chiara; Auletta, S.; Carideo, Luciano; Valabrega, Stefano; Pacilio, Massimiliano; Signore, Alberto; Galli, Filippo. - In: INTERNATIONAL JOURNAL OF NUCLEAR MEDICINE RESEARCH. - ISSN 2408-9788. - ELETTRONICO. - 3(2016), pp. 63-70. [10.15379/2408-9788.2016.03.02.04]

Immunoscintigraphy for therapy decision making and follow-up of biological therapies

LAURI, CHIARA;CARIDEO, LUCIANO;VALABREGA, Stefano
Writing – Review & Editing
;
PACILIO, MASSIMILIANO;SIGNORE, Alberto;GALLI, FILIPPO
Writing – Original Draft Preparation
2016

Abstract

With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets. In this scenario nuclear medicine offers many radiopharmaceuticals for SPECT or PET imaging of many pathological conditions. The availability of monoclonal antibodies provides tools to target specific antigens involved in angiogenesis, cell cycle or modulation of the immune systems. The radiolabelling of such therapeutic mAbs is a promising method to evaluate the antigenic status of each cancer lesion or inflamed sites before starting the therapy. It may also allow to perform follow-up of such biological therapies. In the present review we provide an overview of the most studied radiolabelled antibodies for therapy decision making and follow-up of patients affected by cancer and other pathological conditions.
immunoscintigraphy; nuclear medicine; personalized medicine; radiolabelled mAbs; radiopharmaceuticals
01 Pubblicazione su rivista::01a Articolo in rivista
Immunoscintigraphy for therapy decision making and follow-up of biological therapies / Lauri, Chiara; Auletta, S.; Carideo, Luciano; Valabrega, Stefano; Pacilio, Massimiliano; Signore, Alberto; Galli, Filippo. - In: INTERNATIONAL JOURNAL OF NUCLEAR MEDICINE RESEARCH. - ISSN 2408-9788. - ELETTRONICO. - 3(2016), pp. 63-70. [10.15379/2408-9788.2016.03.02.04]
File allegati a questo prodotto
File Dimensione Formato  
Lauri_Immuniscintigraphy_2016.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 353.06 kB
Formato Adobe PDF
353.06 kB Adobe PDF Visualizza/Apri PDF
Lauri_Immunoscintigraphy_2016.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 357.16 kB
Formato Adobe PDF
357.16 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1063935
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact